Age-Related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: A postmarketing medication safety and surveillance study

Retina

Volumn 31, Issue 6, 2011, Pages 1036-1042

  French, Dustin D ^a   Margo, Curtis E ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

anti VEGF; Bevacizumab; drug safety; exudative age related macular degeneration; pharmacoepidemiology; ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; POSTMARKETING SURVEILLANCE; PROPORTIONAL HAZARDS MODEL; REGISTER; RETINA MACULA AGE RELATED DEGENERATION; SURVIVAL; VETERAN; VETERANS HEALTH;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CAUSE OF DEATH; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PRODUCT SURVEILLANCE, POSTMARKETING; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SURVIVAL RATE; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VETERANS;

EID: 79958250004     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31821dc66f     Document Type: Article

References (23)

1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
2. Brown D, Michels M, Kaisser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmol 2009;116:57-69.
3. Rosenfeld PJ, Brown DM, Heier SJ, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;335:1419-1431. (Pubitemid 44511557)
4. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145:239-248.
5. Schmucker C, Ehlken C, Hansen LL, et al. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol 2010;21:218-226.
6. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety ofintravitreal injections ofbevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clinic Exp Ophthalmol 2008;246:81-87. (Pubitemid 350167096)
7. Friedman DS, O'Colmain BJ, Munoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122: 564-572. (Pubitemid 38456293)
8. Curtis LH, Hannill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associ-ated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-1279.
9. Celmons TE, Kurinji N, Sperduto RD, et al. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the age-related Eye Disease Study. Arch Ophthalmol 2004;122:716-726. (Pubitemid 38607400)
10. Wong TY, Tikelis G, Sun C, et al. Age-related macular degeneration and risk of coronary heart disease; the Athero-sclerosis Risk in Communities Study. Ophthalmology 2007; 114:86-91. (Pubitemid 46014277)
11. Liao D, Mo J, Duan Y, et al. Is age-related macular degen-eration associated with stroke among elderly Americans? Open Ophthalmol J 2008;8:37-42.
12. Duan Y, Mo J, Klein R, et al. Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 2007;114:732-737. (Pubitemid 46483682)
13. Hu CC, Ho JD, Lin HC. Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study. Stroke 2010;41:575-576.
14. Enseleit F, Michels S, Ruschitzka F. Anti-VEGF therapies and blood pressure: more than meets the eye. Curr Hypertens Rep 2010;12:33-38.
15. Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major U.S. mortality databases. Ann Epidemiol 2002;12:462-468.
16. Pope GC, Ellis RP, Ash AS, et al. Diagnostic Cost Group Hierarchical Condition Category models for Medicare Risk Adjustment. Final report. Available at: www.cms.hhs.gov/Reports/downloads/pope-2000-2.pdf. Accessed March 17, 2010. 17.
17. VA Information Resource Center (VIReC). Available at: http://www.virec.research.va.gov. Accessed February 10, 2010.
18. Nelson KM, Starkebaum GA, Reiber GE. Veterans using and uninsured veterans not using Veterans Affairs (VA) health care. Public health Rep 2007;122:93-100.
19. Selim AJ, Kazis Le, Rogers W, et al. Risk-adjusted mortality as an indicator of outcomes: comparison of the Medicare Advantage Program with the Veterans' Health Administration. Med Care 2006;44:359-365. (Pubitemid 43755440)
20. Buch H, Vinding T, la Cour M, et al. Age-related maculopathy: a risk indicator for poorer survival in women. Ophthalmology 2005;112:305-312. (Pubitemid 40202569)
21. Gottlieb SS. Dead is dead\artificial definitions are no substitute. Lancet 1997;349:662-663. (Pubitemid 27107739)
22. LauerMS, BlackstoneEH, YoungJB, TopolEJ. Causeofdeath in clinical research: time for a reassessment? J Am Coll Cardiol 1999;34:618-620. (Pubitemid 29436163)
23. Lauer MS, Topol EJ. Clinical trials\multiple treatments, multiple end points, and multiple lesions. JAMA 2003;289: 275-257.